Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Execs Lobby US Secretaries Ross, Price On Medtech Issues

Executive Summary

A group of top medical device executives led by AdvaMed CEO Scott Whitaker met the US commerce and health secretaries to discuss key industry issues, including device tax repeal, FDA user-fee reauthorization, trade policies and reimbursement.

You may also be interested in...



Trump Budget: 71% Of US FDA Device Funding Would Come From User Fees

The Trump White House is not backing down in its push to renegotiate the US FDA user-fee reauthorization deals that were inked during the Obama administration. The FY 2018 budget request would ask for more than a $200m increase in fees from device companies in the coming fiscal year to counterbalance major cuts in appropriations from Congress. That would make the agency's device program dependent on user fees for about 71% of its budget, versus about 27% currently. But Congress has already said it opposes the plan.

Industry Confident About Device Tax Repeal, But It's Still Vehicle-Shopping

AdvaMed CEO Scott Whitaker says he is as confident as ever that permanent device tax repeal will happen this year. The only question is, he suggests, what legislative vehicle will bring it over the finish line. User-fee and children's health-insurance reauthorizations are options, along with tax reform, he says.

US FDA Adds 14 New Regulatory Tools To Help It Review Medical Devices

The tools include new laboratory methods, and computational models and simulations give the agency more capabilities to test and validate data in premarket submissions.

Topics

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel